Biolidics, Sysmex partner on cancer liquid biopsy development

Biolidics said on that it has partnered with Japanese diagnostics firm Sysmex on the development of a liquid biopsy-based cancer test for the Asian market.

The companies have been collaborating since 2016 on a liquid biopsy system that combines Biolidics’ ClearCell FX1 automated label-free circulating tumor cell separation and enrichment platform with Sysmex’s MI-FCM molecular imaging flow cytometer system.

Under the terms of their latest agreement, the companies will jointly develop a laboratory-developed test based on their respective technologies. Following clinical validation by Biolidics affiliate SAM Laboratory, Biolidics — formerly known as Clearbridge BioMedics — will commercialize the test in Asian markets outside of Japan.

Additional terms were not disclosed.


Related presentations

Liked this post?

Share it on your social networks

Photonics Forums Yole CIOE 2020 1140x370